
|Articles|May 1, 2001
Supplements and Featured Publications
- Artherosclerosis: Achieving Optimal Outcomes in Statin Therapy
- Volume 7
- Issue 5 Suppl
Surrogate Endpoints and Newer Risk Markers in Atherosclerosis Management
Author(s)Christie M. Ballantyne, MD
Advertisement
Articles in this issue
over 24 years ago
Participating Facultyover 24 years ago
Introductionover 24 years ago
Threshold Level or Not for Low-Density Lipoprotein Cholesterolover 24 years ago
Statins--Differences and Similaritiesover 24 years ago
What Do the Statin Trials Tell Us?over 24 years ago
New Therapies on the Horizonover 24 years ago
A New Statin: A New StandardNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5